Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Robert H.I. Andtbacka"'
Autor:
Juan C. Paramo, Sajeve S. Thomas, William Schmidt, Pallavi Kumar, Eddy C. Hsueh, Deepti Behl, Vinay Kumar Gupta, Prejesh Philips, Edward C. McCarron, Arvinda Padmanabhan, Adam C. Berger, Daniel Milton, Tawnya L. Bowles, Robert Weber, Jeffrey B Travers, Brendan D. Curti, Suthee Rapisuwon, Robert H.I. Andtbacka, Peter D. Beitsch, Mohammed M. Milhem, Edward A. Levine, John R. Hyngstrom, Suprith Badarinath, Anna Bar, John Keech, Marcus O. Butler, Omid Hamid, Brian R. Gastman, Andrew L. Pecora, Craig L. Slingluff, Takami Sato, J. Thaddeus Beck, Sekwon Jang, Catalin Mihalcioiu, John A. Glaspy, Karl D. Lewis, Shernan G. Holtan, Joël Claveau, Montaser Shaheen, Leonel Hernandez-Aya, Jose Lutzky, Brent A. Blumenstein, Joanna J Peterkin, Svetomir N. Markovic, Sujith Kalmadi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundMost patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing human melanoma antigens, plu
Publikováno v:
Cancer Research. 75:B13-B13
Background: The risk of recurrence and death in patients (pts) with stages IIIB to IVM1a melanoma following resection is high. T-VEC is an HSV-1 derived oncolytic immunotherapy designed to selectively replicate in tumors and produce GM-CSF to enhance